IP Library › Granted Patent US 10,874,659
Granted Patent B2
US 10,874,659 · App. 14/384,401 · Granted Dec 29, 2020

Iloperidone metabolite for use in the treatment of psychiatric disorders

Inventors: Deepak Phadke (Olathe, KS); Curt D. Wolfgang (Germantown, MD); Mihael H. Polymeropoulos (Potomac, MD); John Joseph Feeney (Olney, MD); Gunther Birznieks (Bethesda, MD)
Assignee: Vanda Pharmaceuticals Inc.
A61K31/454A61P25/18
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,874,659
App. No.
14/384,401
Granted
Dec 29, 2020
Kind
B2
Abstract

R-P88 is used for the treatment of disorders amenable to treatment with an atypical antipsychotic.

Claims (19)

1. A method of treating a patient suffering from a psychiatric disorder that comprises internally administering to the patient R-P88, or a pharmaceutically acceptable salt thereof, or an ester of R-P88, or a pharmaceutically acceptable salt of such ester, once per day, titrated to a final dose in accordance with one of the following increments:

1 mg once daily, 2 mg once daily, 4 mg once daily, 6 mg once daily, 8 mg once daily, 10 mg once daily, 12 mg once daily, to reach a maximum dose of 12 mg/day; or

2 mg once daily, 4 mg once daily, 8 mg once daily, 12 mg once daily, to reach a maximum dose of 12 mg/day; or

1 mg once daily, 4 mg once daily, 8 mg once daily, and 12 mg once daily, to reach a maximum dose of 12 mg/day; or

2 mg once daily, 6 mg once daily, and 12 mg once daily, to reach a maximum dose of 12 mg/day.

2. The method of claim 1 wherein the disorder is one that is amenable to treatment with iloperidone.

3. The method of claim 1 wherein the disorder is one or more of schizophrenia, schizoaffective disorder, bipolar disorder (mania and/or depression), depression, major depression, psychotic episodes, autism, autism spectrum disorder, fragile X syndrome, and pervasive developmental disorder.

4. The method of claim 1 , wherein the R-P88, or the pharmaceutically acceptable salt thereof, or the ester of R-P88, or the pharmaceutically acceptable salt of such ester, is orally administered.

5. A method of treating a patient suffering from a psychiatric disorder that comprises internally administering to the patient R-P88, or a pharmaceutically acceptable salt thereof, or an ester of R-P88, or a pharmaceutically acceptable salt of such ester, twice per day, titrated in accordance with one of the following increments:

1 mg twice daily, 2 mg twice daily, and 3 mg twice daily, to reach a maximum dose of 6 mg/day; or

1 mg twice daily, 2 mg twice daily, 3 mg twice daily, 4 mg twice daily, 5 mg twice daily and 6 mg twice daily, to reach a maximum dose of 12 mg/day; or

1 mg twice daily, 2 mg twice daily, 4 mg twice daily, 6 mg twice daily, 8 mg twice daily, to reach a maximum dose of 16 mg/day; or

1 mg twice daily, 4 mg twice daily, and 6 mg twice daily, to reach a maximum dose of 12 mg/day; or

2 mg twice daily and 6 mg twice daily, to reach a maximum dose of 12 mg/day.

6. The method of claim 5 wherein the disorder is one that is amenable to treatment with iloperidone.

7. The method of claim 5 , wherein the R-P88, or pharmaceutically acceptable salt thereof, or ester of R-P88, or pharmaceutically acceptable salt of such ester, is titrated in accordance with the following schedule:

1 mg b.i.d. on day 1, 2 mg b.i.d. on day 2, 3 mg b.i.d. on day 3 and thereafter; or

1 mg b.i.d. on day 1, 2 mg b.i.d. on day 2, 3 mg b.i.d. on day 3, 4 mg b.i.d. on day 4, 5 mg b.i.d. on day 5, 6 mg b.i.d. on day 6 and thereafter; or

1 mg b.i.d. on day 1, 2 mg b.i.d. on day 2, 4 mg b.i.d. on day 3, 6 mg b.i.d. on day 4, 8 mg b.i.d. on day 5 and thereafter.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 27, 2014
From: PHADKE, DEEPAK; WOLFGANG, CURT D.; POLYMEROPOULOS, MIHAEL H.; BIRZNIEKS, GUNTHER
To: VANDA PHARMACEUTICALS, INC.
Reel/Frame 034036/0322 →
Continuity (2)
Provisional Application 61610664 · Mar 14, 2012
Related Publication 20150045390A1 · Feb 12, 2015
Cited By (2)
US 12,478,619 US 12,606,869